drugset / Trial / NCT04104776
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid tumors and lymphomas.
Timeline
- Start
- 2019-09-18
- Primary completion
- 2030-02-27
- Completion
- 2030-02-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |
| Subject | Tulmimetostat | Small molecule | 200 mg | Oral |
| Subject | Tulmimetostat | Small molecule | 300 mg | Oral |